<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04995185</url>
  </required_header>
  <id_info>
    <org_study_id>MISSION16</org_study_id>
    <nct_id>NCT04995185</nct_id>
  </id_info>
  <brief_title>18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study</brief_title>
  <official_title>18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terry Fox Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Centre, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the use of 18F-FMISO PET in identifying hypoxic subvolume for&#xD;
      dose escalation radiotherapy in nasopharyngeal cancer and thus improve local control without&#xD;
      significant increase in toxicities.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The specific aims of this study are:&#xD;
&#xD;
        1. To establish hypoxia imaging in NPC patients&#xD;
&#xD;
        2. Investigate the dynamics of tumor hypoxia before and during chemoradiation&#xD;
&#xD;
        3. Integrate hypoxia imaging into radiation treatment planning protocols&#xD;
&#xD;
        4. Design hypoxia adapted radiation schedules&#xD;
&#xD;
        5. Identify candidate hypoxia biomarkers&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Actual">December 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the dynamics of tumour hypoxia</measure>
    <time_frame>From baseline and during 7 week long treatment regimen</time_frame>
    <description>A repeat 18F-FMISO-PET in week 3 of the 7 weeks long treatment regimen is planned. Fractionated radiotherapy is expected to induce reoxygenation within the tumor as iterative process by killing well oxygenated tumor cells with every fraction thereby reducing oxygen demand in the remaining tumor cells. Repetitive hypoxia imaging at week 3 allows for assessment of evolution of hypoxia during radiotherapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate proportion of patients with contour-able hypoxic volume as well as the feasibility of generating dose-escalation radiotherapy plan with dosimetrically achieved parameters for target volume and organs-at-risk.</measure>
    <time_frame>At baseline and week 3 of RT</time_frame>
    <description>Number of patients with feasible radiotherapy plan dose-escalation to more than 84Gy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To estimate the correlation between immunohistochemical expression of CA-IX, VEGF and HIF-1a, (marker of hypoxia) and pre-treatment PET-SUV measurement</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To correlate 18F-FMISO PET uptake with tumor response at 3 months post radiotherapy, local control rate and disease free survival.</measure>
    <time_frame>From baseline up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>PET/CT imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>(18)F-fluoromisonidazole (FMISO)</intervention_name>
    <description>Patients do not need to be fasted prior to intravenous injection of 370MBq ± 10% (18)F-fluoromisonidazole. Scanning will be performed two hours after the injection. Patients will be scanned with their thermoplastic shell used in routine radiotherapy treatment for 10 minutes, followed by approximately 5 minutes scan of the upper chest.</description>
    <arm_group_label>PET/CT imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T3-T4 disease with no evidence of distant metastasis.&#xD;
&#xD;
          -  Histological diagnosis of WHO Type II or III NPC&#xD;
&#xD;
          -  No evidence of distant metastases in staging work up (including lung, liver and bone&#xD;
             imaging).&#xD;
&#xD;
          -  Planned for upfront radiotherapy and/or chemotherapy.&#xD;
&#xD;
          -  Cross sectional imaging of the primary and neck disease (MRI preferred)&#xD;
&#xD;
          -  Performance status of ECOG grade 0 or 1&#xD;
&#xD;
          -  No prior tumour therapy&#xD;
&#xD;
          -  At least 21 years of age, of either sex.&#xD;
&#xD;
          -  Negative serum pregnancy test within 14 days prior to registration for women of&#xD;
             childbearing potential;&#xD;
&#xD;
          -  Adequate bone marrow, renal and hepatic function defined as follows:&#xD;
&#xD;
        Bone marrow: WBC &gt; 3000 / mm3 (ANC &gt; 1500 / mm3 ) Platelets &gt; 100 000 / mm3. Hb &gt; 10 gm/dl&#xD;
        Renal: serum creatinine within institutional normal range(or) lower than the lower limit of&#xD;
        institutional normal range : calculated creatinine clearance &gt; 50 ml / min Hepatic: enzymes&#xD;
        (SAP, SGOT) &lt; 2x normal: bilirubin &lt; 24 mol / l.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergic to 18F-fluoromisonidazole or Nitroimidazoles&#xD;
&#xD;
          -  Planned for neoadjuvant chemotherapy&#xD;
&#xD;
          -  Uncontrolled hypercalcaemia: calcium 2.7 mmol/L (10.8 mg/dL).&#xD;
&#xD;
          -  Other serious concomitant systemic disorders incompatible with the study (at the&#xD;
             discretion of the investigator).&#xD;
&#xD;
          -  Have serious active infection.&#xD;
&#xD;
          -  Pregnant or lactating female subjects and subjects with reproductive potential not&#xD;
             implementing adequate contraceptive measures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiattisa Sommat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre, Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 29, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypoxia</keyword>
  <keyword>FMISO</keyword>
  <keyword>PET</keyword>
  <keyword>Nasopharyngeal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

